CanCuRX

Company Overview

Snapshot

Founded in February 2016 by Prof. Fuad Fares and Lital Sharvit, CanCuRX operates with 1–10 employees. CanCuRX holds patents for its mushroom strain, the extract derived from it, and the associated treatment process.

Business overview

CanCuRX is a preclinical-stage biopharmaceutical company focused on developing a novel treatment for pancreatic cancer. The company's core technology leverages a mushroom-derived compound designed to arrest pancreatic cell growth. CanCuRX operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals industry with its biopharmaceutical solutions.

Strategic signal

In January 2019, news highlighted Prof. Fuad Fares, a co-founder of CanCuRX, as a Druze hi-tech pioneer. This recognition underscores the innovative foundation and leadership driving CanCuRX's efforts in biopharmaceutical development, signaling potential for future advancements and industry impact.

Company Intelligence Q&A

What is CanCuRX's primary focus?

CanCuRX is a preclinical-stage biopharmaceutical company dedicated to improving survival for patients with pancreatic cancer through a novel treatment.

What is the basis of CanCuRX's treatment technology?

CanCuRX's treatment is based on the properties of a mushroom-derived compound that has demonstrated the ability to arrest pancreatic cell growth.

When was CanCuRX founded and by whom?

CanCuRX was founded in February 2016 by Prof. Fuad Fares and Lital Sharvit.

Does CanCuRX hold any patents?

Yes, CanCuRX has registered patents for its mushroom strain, the extract prepared from it, and the treatment process.

What is the current development stage of CanCuRX's product?

CanCuRX's product is currently in the R&D stage, with the company operating as a preclinical-stage biopharmaceutical entity.